hCG progression in early pregnancy: what the data says

What did @birdandbe actually say?

In a reply video, Dr. Prati Sharma, described as a double board-certified OB/GYN and REI, walked through what normal hCG progression looks like in early pregnancy. She said hCG levels should "rise or double every two to three days" but clarified that a rise "as low as 66%" over that window can still indicate a healthy, viable intrauterine pregnancy. She also outlined a monitoring protocol: check hCG every two to three days, approximately three to four times, starting around 4.5 weeks gestation or 8 to 12 days after a blastocyst embryo transfer.

That is a reasonably specific clinical framework, and it is worth checking against the literature rather than just taking it at face value, even from a specialist.

Does the science back this up?

Mostly, yes. The 66% minimum rise threshold is well-supported, and the advice against rigid "doubling every 48 hours" expectations is actually better medicine than what many patients hear.

The 66% figure comes from a widely cited 2004 study by Barnhart et al. published in Obstetrics and Gynecology, which analyzed serial hCG values in pregnancies of known outcome. That study found that the slowest rise seen in a viable intrauterine pregnancy over 48 hours was approximately 53%, though the 66% threshold has become the clinical standard as a conservative, practical cutoff. A 2012 follow-up by Silva et al. in the same journal reinforced that rigid doubling expectations miss a meaningful proportion of viable pregnancies. So Dr. Sharma is correct to push back on the old "must double every two days" rule. Where she is slightly imprecise is in consistently saying "two to three days" when the 66% threshold in the literature is anchored to a 48-hour interval, not 72 hours. That distinction matters in practice.

What did they get right, and where does it get fuzzy?

Credit where it is due: the core message that "doubling" is not a hard requirement is accurate and genuinely useful for patients who have been told otherwise. Unnecessary anxiety from slight underperformers is a real clinical problem.

The fuzziness is in the framing. Saying a 66% rise "every two to three days" conflates two different benchmarks. The 66% minimum is a 48-hour standard. Over 72 hours, the expected rise is considerably higher, and a 66% rise over three days would actually be concerning. The Barnhart 2004 data puts the minimum 48-hour rise for viable IUP at roughly 53-66%, but by 72 hours, viable pregnancies show much steeper increases. Dr. Sharma does not make that distinction explicit, which could leave a patient thinking a sluggish 66% rise over three days is fine when it may not be. That is a meaningful gap in an otherwise solid explanation. The monitoring timeline she describes, three to four checks spaced two to three days apart, aligns with standard REI practice and is not controversial.

What should you actually know?

If you are tracking hCG after a transfer or IUI, here is what the data actually supports.

• A 66% rise over 48 hours is the minimum threshold for a potentially viable intrauterine pregnancy, not over 72 hours. The time interval matters.
• A single hCG number tells you almost nothing. Trajectory is what matters, which is why serial draws exist.
• An hCG that rises appropriately does not confirm a healthy pregnancy. It rules out some bad outcomes. Ultrasound confirmation around 6 to 7 weeks is still required to confirm viability and location (Barnhart et al., 2004, Obstetrics and Gynecology).
• Ectopic pregnancies can produce rising hCG values, sometimes even meeting the 66% threshold. A rising beta does not mean you are in the clear if you have risk factors for ectopic pregnancy.
• Very high initial hCG values, often seen with multiples or molar pregnancies, follow different curves. The 66% rule applies most reliably to singleton pregnancies in the early first trimester.

If your numbers are not following the expected pattern, that is a conversation for your reproductive endocrinologist, not a TikTok comment section. Dr. Sharma's video is a reasonable starting point, but it is not a substitute for individualized clinical interpretation of your actual results.